Myrtelle releases interim data from gene therapy trial for Canavan disease

Myrtelle has published interim results from its Phase 1/2 trial of the investigational gene therapy rAAV-Olig001-ASPA (MYR-101) in Nature Medicine, reporting changes in biomarkers, imaging and functional measures in children with Canavan disease, according to the company. The trial includes eight ch…